Literature DB >> 10825167

Role of the intracellular domain of the human type I interferon receptor 2 chain (IFNAR2c) in interferon signaling. Expression of IFNAR2c truncation mutants in U5A cells.

D Russell-Harde1, T C Wagner, M R Rani, D Vogel, O Colamonici, R M Ransohoff, B Majchrzak, E Fish, H D Perez, E Croze.   

Abstract

A human cell line (U5A) lacking the type I interferon (IFN) receptor chain 2 (IFNAR2c) was used to determine the role of the IFNAR2c cytoplasmic domain in regulating IFN-dependent STAT activation, interferon-stimulated gene factor 3 (ISGF3) and c-sis-inducible factor (SIF) complex formation, gene expression, and antiproliferative effects. A panel of U5A cells expressing truncation mutants of IFNAR2c on their cell surface were generated for study. Janus kinase (JAK) activation was detected in all mutant cell lines; however, STAT1 and STAT2 activation was observed only in U5A cells expressing full-length IFNAR2c and IFNAR2c truncated at residue 462 (R2.462). IFNAR2c mutants truncated at residues 417 (R2. 417) and 346 (R2.346) or IFNAR2c mutant lacking tyrosine residues in its cytoplasmic domain (R2.Y-F) render the receptor inactive. A similar pattern was observed for IFN-inducible STAT activation, STAT complex formation, and STAT-DNA binding. Consistent with these data, IFN-inducible gene expression was ablated in U5A, R2.Y-F, R2.417, and R2.346 cell lines. The implications are that tyrosine phosphorylation and the 462-417 region of IFNAR2c are independently obligatory for receptor activation. In addition, the distal 53 amino acids of the intracellular domain of IFNAR2c are not required for IFN-receptor mediated STAT activation, ISFG3 or SIF complex formation, induction of gene expression, and inhibition of thymidine incorporation. These data demonstrate for the first time that both tyrosine phosphorylation and a specific domain of IFNAR2c are required in human cells for IFN-dependent coupling of JAK activation to STAT phosphorylation, gene induction, and antiproliferative effects. In addition, human and murine cells appear to require different regions of the cytoplasmic domain of IFNAR2c for regulation of IFN responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825167     DOI: 10.1074/jbc.M002518200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.

Authors:  Rebecca A R Piganis; Nicole A De Weerd; Jodee A Gould; Christian W Schindler; Ashley Mansell; Sandra E Nicholson; Paul J Hertzog
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

2.  Receptor density is key to the alpha2/beta interferon differential activities.

Authors:  Ignacio Moraga; Daniel Harari; Gideon Schreiber; Gilles Uzé; Sandra Pellegrini
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

3.  New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain.

Authors:  Laure Dumoutier; Carole de Meester; Jan Tavernier; Jean-Christophe Renauld
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

4.  Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency.

Authors:  Paul Bastard; Jeremy Manry; Jie Chen; Jérémie Rosain; Yoann Seeleuthner; Omar AbuZaitun; Lazaro Lorenzo; Taushif Khan; Mary Hasek; Nicholas Hernandez; Benedetta Bigio; Peng Zhang; Romain Lévy; Shai Shrot; Eduardo J Garcia Reino; Yoon-Seung Lee; Soraya Boucherit; Mélodie Aubart; Rik Gijsbers; Vivien Béziat; Zhi Li; Sandra Pellegrini; Flore Rozenberg; Nico Marr; Isabelle Meyts; Bertrand Boisson; Aurélie Cobat; Jacinta Bustamante; Qian Zhang; Emmanuelle Jouangy; Laurent Abel; Raz Somech; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

5.  STAT-phosphorylation-independent induction of interferon regulatory factor-9 by interferon-beta.

Authors:  M R Sandhya Rani; Ed Croze; Tao Wei; Jennifer Shrock; Anupama Josyula; Dhananjaya V Kalvakolanu; Richard M Ransohoff
Journal:  J Interferon Cytokine Res       Date:  2010-03       Impact factor: 2.607

6.  Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.

Authors:  Eleftherios Michailidis; Hans-Heinrich Hoffmann; Marwa Chbihi; Stephen J Seligman; Qian Zhang; Margaret R MacDonald; Emmanuelle Jouanguy; Charles M Rice; Jean-Laurent Casanova; Paul Bastard; Tom Le Voyer; Jérémie Rosain; Quentin Philippot; Yoann Seeleuthner; Adrian Gervais; Marie Materna; Patricia Mouta Nunes de Oliveira; Maria de Lourdes S Maia; Ana Paula Dinis Ano Bom; Tamiris Azamor; Deborah Araújo da Conceição; Ekaterini Goudouris; Akira Homma; Günther Slesak; Johannes Schäfer; Bali Pulendran; Joseph D Miller; Ralph Huits; Rui Yang; Lindsey B Rosen; Lucy Bizien; Lazaro Lorenzo; Maya Chrabieh; Lucia V Erazo; Flore Rozenberg; Mohamed Maxime Jeljeli; Vivien Béziat; Steven M Holland; Aurélie Cobat; Luigi D Notarangelo; Helen C Su; Rafi Ahmed; Anne Puel; Shen-Ying Zhang; Laurent Abel
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

Review 7.  JAK/STAT: Why choose a classical or an alternative pathway when you can have both?

Authors:  Léna Puigdevall; Camille Michiels; Clara Stewardson; Laure Dumoutier
Journal:  J Cell Mol Med       Date:  2022-03-03       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.